CONSTANT LEVERAGE LONG - ELI LILLY & CO | Market Closed - Euronext Paris 10:00:02 15/05/2024 pm IST | ||
| 9.02 EUR | +15.05% |
|
| Current month | -4.30% | ||
| 1 month | +0.49% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 15/24/15 | 9.02 | +15.05% |
| 14/24/14 | 7.84 | 0.00% |
| 13/24/13 | 7.84 | -6.39% |
| 10/24/10 | 8.375 | -5.79% |
| 09/24/09 | 8.89 | -1.88% |
Real-time Euronext Paris
Last update May 15, 2024 at 10:00 pm IST
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
BNP Paribas
|
| WL5NB | |
| ISIN | NLBNPNL2OS18 |
| Date issued | 13/03/2024 |
| Maturity | Unlimited |
| Parity | 1 : 1 |
| Emission price | - € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 11.53 € |
|---|---|
| Lowest since issue | 6.785 € |
| Spread | 0.12 € |
| Spread % | 1.32% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
764
USD
Average target price
850.4
USD
Spread / Average Target
+11.31%
- Stock Market
- Certificates
- WL5NB Certificat
